BACKGROUND: Thyroid cancer patients should be on low-iodine diet (LID) before radioactive iodine therapy (RAIT) to maximize the effect of RAIT. Urinary iodine excretion is the most accurate marker of very recent dietary iodine intake. We developed and evaluated the analytical performance of inductively coupled plasma-mass spectrometry (ICP-MS) to determine urinary iodine concentration. METHODS: We evaluated the linearity, precision, accuracy, and lower limit of quantification (LLOQ) of an ICP-MS method (Agilent 7500ce) to determine urinary iodine concentration in accordance with the Food and Drug Administration (FDA) guidelines for bioanalytical method validation. This method was used to determine and compare the iodine concentration in random urine samples of 120 thyroid cancer patients on LID for 1 week and 80 healthy adults on normal diet. RESULTS: Our ICP-MS method showed good linearity (1.0-1,913 microg/L; R(2)>0.999). Both intra-day and inter-day precision CV were within 20% for the LLOQ (1 microg/L) and within 15% for the other concentrations. Accuracy was 110-120% for the LLOQ and 95-115% for the other concentrations. The median concentration of iodine in random urine samples from thyroid cancer patients on LID (38.7 microg/L) was significantly lower than that of healthy subjects (238.8 microg/L) (P<0.0001). CONCLUSIONS: Urinary iodine analysis by ICP-MS showed good linearity, precision, accuracy, wide measuring range of detection, and lower LLOQ. This method will be very useful to evaluate the status of dietary iodine intake and the appropriateness of LID in thyroid cancer patients, thereby maximizing the effect of RAIT.
BACKGROUND:Thyroid cancerpatients should be on low-iodine diet (LID) before radioactive iodine therapy (RAIT) to maximize the effect of RAIT. Urinary iodine excretion is the most accurate marker of very recent dietary iodine intake. We developed and evaluated the analytical performance of inductively coupled plasma-mass spectrometry (ICP-MS) to determine urinary iodine concentration. METHODS: We evaluated the linearity, precision, accuracy, and lower limit of quantification (LLOQ) of an ICP-MS method (Agilent 7500ce) to determine urinary iodine concentration in accordance with the Food and Drug Administration (FDA) guidelines for bioanalytical method validation. This method was used to determine and compare the iodine concentration in random urine samples of 120 thyroid cancerpatients on LID for 1 week and 80 healthy adults on normal diet. RESULTS: Our ICP-MS method showed good linearity (1.0-1,913 microg/L; R(2)>0.999). Both intra-day and inter-day precision CV were within 20% for the LLOQ (1 microg/L) and within 15% for the other concentrations. Accuracy was 110-120% for the LLOQ and 95-115% for the other concentrations. The median concentration of iodine in random urine samples from thyroid cancerpatients on LID (38.7 microg/L) was significantly lower than that of healthy subjects (238.8 microg/L) (P<0.0001). CONCLUSIONS: Urinary iodine analysis by ICP-MS showed good linearity, precision, accuracy, wide measuring range of detection, and lower LLOQ. This method will be very useful to evaluate the status of dietary iodine intake and the appropriateness of LID in thyroid cancerpatients, thereby maximizing the effect of RAIT.